CU6

Clarity Pharmaceuticals

Pharmaceuticals, Biotechnology & Life Sciences

Clarity Pharmaceuticals is a clinical-stage company specializing in radiopharmaceuticals, focusing on theranostic products that combine therapy and imaging. Utilizing its proprietary SAR Technology, Clarity aims to improve cancer treatment outcomes with its Targeted Copper Theranostic platform. The company is positioned as a leader in next-generation radiopharmaceuticals, offering products that pr...

Radiopharmaceuticals

Theranostics

Oncology

SAR Technology

Shorted

short percentage6.93%

reported shorts25.8M

shares on issue372.030M

Shorted

short percentage

reported short positions

total shares on issue

About

website

claritypharmaceuticals.com

industry

Pharmaceuticals, Biotechnology & Life Sciences

address

'National Innovation Centre', Suite 212a 2-4 Cornwallis Street, EVELEIGH, NSW, AUSTRALIA, 2015

Connect

Key Metrics

market cap

$1.07B

eps$-0.20

More Pharmaceuticals, Biotechnology & Life Sciences Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

Radiopharmaceuticals

Theranostics

Oncology

SAR Technology

Copper Isotopes

Company Overview

AI-generated company summary

Company History

Clarity Pharmaceuticals was founded with the mission to develop innovative radiopharmaceutical products for cancer treatment. Over the years, the company has evolved into a leader in the field, leveraging its SAR Technology to create a robust pipeline of theranostic products. Major milestones include the development of core products like SAR-bisPSMA, SAR-Bombesin, and SARTATE, which are in various stages of clinical development. Clarity's focus on copper isotopes has allowed it to address unmet clinical needs in oncology.

Competitive Advantages

Clarity Pharmaceuticals' competitive advantages include its proprietary SAR Technology platform, which enables the development of highly targeted theranostic products. The use of copper isotopes provides logistical and supply advantages over traditional theranostics. Additionally, Clarity's robust intellectual property portfolio supports its leadership position in the radiopharmaceutical market.

Risk Factors

•Regulatory approval challenges
•Clinical trial risks
•Market competition

Recent Developments

Last 6 months

In the last six months, Clarity Pharmaceuticals has continued to advance its clinical trials for its core theranostic products. The company has also released several financial reports, indicating ongoing strategic initiatives and financial health.

Key People

Leadership team at Clarity Pharmaceuticals

Michelle Parker

Chief Executive Officer, Managing Director

Ms. Parker is a long-time member of Clarity’s senior executive team, having joined the Company in June 2018. She has played a pivotal role in driving the company's strategic initiatives and growth.

Robert Vickery

Chief Financial Officer

Robert joined Clarity in July 2019 as the Chief Financial Officer and is now also serving as Company Secretary. He brings extensive financial expertise to the company, supporting its financial strategy and operations.